Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,320 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: docetaxel Clear all
Not listed Phase 2 Interventional

Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT00003560
View directory record Official record
Conditions
Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
carboplatin, docetaxel
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 23, 2026, 3:30 PM EDT
Terminated Phase 2 Interventional Results available

Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

NCT00707473
View directory record Official record
Conditions
Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma, Sinonasal Undifferentiated Carcinoma, Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC v8, Stage III Nasal Cavity and Paranasal Sinus Cancer AJCC v8, Stage IVA Nasal Cavity and Paranasal Sinus Cancer AJCC v8, Stage IVB Nasal Cavity and Paranasal Sinus Cancer AJCC v8
Interventions
Carboplatin, Chemoradiotherapy, Cisplatin, Definitive Surgical Resection, Docetaxel, Fluorouracil, Quality-of-Life Assessment, Radiation Therapy
Drug · Other · Procedure + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
17 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 23, 2026, 3:30 PM EDT
Completed Phase 1Phase 2 Interventional

Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors

NCT00004923
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
docetaxel, irinotecan hydrochloride
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
2
States / cities
New Haven, Connecticut • Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 25, 2009 · Synced Oct 23, 2026, 3:30 PM EDT
Completed Phase 2 Interventional Results available

Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer

NCT00271505
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Bevacizumab (Avastin), Carboplatin, Docetaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 23, 2026, 3:30 PM EDT
Completed Phase 2 Interventional Results available

Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC

NCT00130780
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pre-surgical Treatment with Bevacizumab plus Chemotherapy, Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 23, 2026, 3:30 PM EDT
Terminated Phase 1 Interventional

Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer

NCT00042835
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
cisplatin, etoposide, erlotinib hydrochloride, radiation therapy, docetaxel, paclitaxel, carboplatin, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 23, 2026, 3:30 PM EDT
Completed Not applicable Interventional

Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus

NCT00614835
View directory record Official record
Conditions
Uterine Leiomyosarcoma, Uterine Cancer
Interventions
Docetaxel plus Gemcitabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Oct 23, 2026, 3:30 PM EDT
Completed Phase 1 Interventional

Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005627
View directory record Official record
Conditions
Prostate Cancer
Interventions
carboplatin, docetaxel, estramustine phosphate sodium
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 85 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 23, 2026, 3:30 PM EDT
Completed Phase 2 Interventional

Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer

NCT00050596
View directory record Official record
Conditions
Prostate Cancer
Interventions
MDX-010 / MDX-010 + Docetaxel
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
11
States / cities
Tucson, Arizona • Long Beach, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 23, 2026, 3:30 PM EDT
Terminated Phase 1 Interventional

Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer

NCT01155791
View directory record Official record
Conditions
Urologic Neoplasms, Prostate Cancer, Prostate Cancer Metastatic Disease
Interventions
Docetaxel, Biosyn, Prednisone
Drug
Lead sponsor
Sandy Srinivas
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 23, 2026, 3:30 PM EDT
Active, not recruiting Phase 3 Interventional

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

NCT04592913
View directory record Official record
Conditions
Gastrointestinal Neoplasms, Esophagogastric Junction
Interventions
Durvalumab, FLOT chemotherapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 200 Years
Enrollment
957 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Sylmar, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 23, 2026, 3:30 PM EDT
Withdrawn Phase 1 Interventional

A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer

NCT01685489
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Docetaxel, PSK®, Docetaxel, Placebo
Drug
Lead sponsor
Bastyr University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Oct 23, 2026, 3:30 PM EDT
Completed Phase 1 Interventional

Taxotere/Temodar/Cisplatin Study in Melanoma Patients

NCT00527761
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Cisplatin, Docetaxel, Temodar
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 23, 2026, 3:30 PM EDT
Terminated Phase 1 Interventional

A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies

NCT01705483
View directory record Official record
Conditions
Pharmacokinetics of ASP9853, Non-hematologic Malignancies
Interventions
ASP9853, Docetaxel, Paclitaxel
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Boston, Massachusetts • Detroit, Michigan • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 23, 2026, 3:30 PM EDT
Completed Phase 1Phase 2 Interventional

ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer

NCT00477529
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer
Interventions
ABI-008
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
4
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 23, 2026, 3:30 PM EDT
Completed Phase 2 Interventional Results available

Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel

NCT01051570
View directory record Official record
Conditions
Prostate Cancer
Interventions
carboplatin, RAD 001, prednisone, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
Evanston, Illinois • Detroit, Michigan • Farmington Hills, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 23, 2026, 3:30 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients

NCT00270894
View directory record Official record
Conditions
Breast Neoplasm
Interventions
epirubicin, cyclophosphamide, docetaxel, trastuzumab
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
7
States / cities
Miami, Florida • Augusta, Georgia • Macon, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Oct 23, 2026, 3:30 PM EDT
Withdrawn Phase 2 Interventional

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

NCT06060587
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, ADT, Abiraterone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 23, 2026, 3:30 PM EDT
Completed Phase 3 Interventional

Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma

NCT00142571
View directory record Official record
Conditions
Sarcoma, Soft Tissue
Interventions
Gemcitabine, Docetaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
10 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2007 · Synced Oct 23, 2026, 3:30 PM EDT
Completed Phase 2 Interventional

Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer

NCT00031187
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
SGN-15 (cBR96-doxorubicin immunoconjugate), Taxotere (docetaxel)
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
11
States / cities
Tucson, Arizona • Springdale, Arkansas • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2011 · Synced Oct 23, 2026, 3:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

NCT02494921
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel-PNP, Ribociclib, Prednisone, Filgrastim
Drug
Lead sponsor
Rahul Aggarwal
Other
Eligibility
18 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
6
States / cities
San Francisco, California • Chicago, Illinois • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 23, 2026, 3:30 PM EDT
Completed Phase 2 Interventional

SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN

NCT02057107
View directory record Official record
Conditions
Previously-Irradiated, Squamous Cell Carcinoma of the Head and Neck Cancer
Interventions
SBRT, Cetuximab, Docetaxel
Radiation · Drug
Lead sponsor
Heath Skinner
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 23, 2026, 3:30 PM EDT
Terminated Phase 3 Interventional Results available

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

NCT02654587
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
OSE2101, Docetaxel, Pemetrexed
Biological · Drug
Lead sponsor
OSE Immunotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Burbank, California • Washington D.C., District of Columbia • Boca Raton, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 23, 2026, 3:30 PM EDT
Not listed Phase 1Phase 2 Interventional

Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)

NCT00082472
View directory record Official record
Conditions
NSCLC
Interventions
Doxorubicin HCl Inhalation Solution, Docetaxel, Cisplatin
Drug
Lead sponsor
Zivena
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
6
States / cities
New Haven, Connecticut • Las Vegas, Nevada • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2006 · Synced Oct 23, 2026, 3:30 PM EDT